Approximately 20% of high-grade ovarian serous carcinomas have germline mutations in the BRCA1 and BRCA2 genes, and 95% of these tumors have somatic mutations in the TP53 genes with loss of p53 protein function.29Germline mutations in the BRCA1 and BRCA2 genes predispose to the development of somatic mutations in the TP53 genes. The gene discussed is TP53; the disease is ovarian serous carcinoma.